As of Q4'25, ABBV reported R&D Expenses of USD 2.58B and SG&A Expenses of USD 3.90B, marking the highest quarterly operating expenses in the observed period. This latest data point reflects a continued increase in both categories, with SG&A Expenses remaining the dominant component of total operating costs. From Q1'23 to Q4'25, ABBV's operating expenses have shown a generally upward trend, with notable volatility in R&D Expenses—particularly a sharp spike to USD 6.77B in Q4'24 before normalizing in subsequent quarters. SG&A Expenses have also trended higher, peaking at USD 4.21B in Q3'24, and consistently outpacing R&D Expenses throughout the period. The data suggests rising investment in both research and administrative functions, with occasional significant fluctuations likely driven by one-off events or strategic initiatives.